GERINDA THERAPEUTICS, INC

Basic Information

1001 SHELDON DR
CARY, NC, 27513-2012

Company Profile

n/a

Additional Details

Field Value
DUNS: 9695452
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. New ultra-selective kinase inhibitors for the treatment of AML

    Amount: $248,481.00

    DESCRIPTION (provided by applicant): Acute Myeloid Leukemia (AML) accounts for a high percentage of all adult leukemia cases. Although most patients at first respond well to conventional chemotherapy, ...

    SBIR Phase I 2012 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government